Jiangsu Yabang Epson Pharmaceutical Co Ltd.

Primary Objective: To evaluate the bioequivalence of ezetimibe-atorvastatin calcium tablets (II) (containing 10 mg ezetimibe and 20 mg atorvastatin calcium per tablet, calculated as atorvastatin) manufactured by N.V. Organon as the reference formulation and ezetimibe-atorvastatin calcium tablets (II) (containing 10 mg ezetimibe and 20 mg atorvastatin calcium per tablet, calculated as atorvastatin) developed by Jiangsu Yabang Aipusen Pharmaceutical Co., Ltd. as the test formulation in healthy participants in a Chinese trial under fasting conditions. Secondary Objective: To observe the safety of the test and reference formulations in healthy participants in a Chinese trial.

The main purpose of the study is to use the upadacitinib extended-release tablets (trade name: RINVOQ®) certified by AbbVie Deutschland GmbH & Co. KG as the reference preparation and the upadacitinib extended-release tablets produced by Jiangsu Yabang Epson Pharmaceutical Co., Ltd. as the test preparation to evaluate the bioequivalence of the two preparations in the fasting and fed state in a single-center, randomized, open, single-dose, two-cycle, double-crossover clinical study. Secondary purpose of the study: to observe the safety of the test preparation and the reference preparation in Chinese health research participants.

Main research purpose: Using Telmisartan Amlodipine Tablets (Specification: 40 mg/5 mg) developed by Jiangsu Yabang Epson Pharmaceutical Co., Ltd. as the test preparation, according to the relevant provisions of bioequivalence studies, the relative bioavailability in healthy humans was compared with Telmisartan Amlodipine Tablets (reference preparation, trade name: Twynsta®, specification: 40 mg/5 mg) certified by Boehringer Ingelheim International GmbH, and the human bioequivalence of the two preparations was investigated. Secondary research purpose: To observe the safety of the test preparation and the reference preparation in healthy participants.